Dispute over drug prices US price pressure threatens new medicines in Switzerland

The Swiss federal council has been urged to abandon proposed discounts on high-revenue medications, according to the National Council’s Health Commission. The commission warned that such measures could jeopardize access to new treatments. The decision comes amid growing concerns over how pricing policies in the United States are affecting pharmaceutical innovation and availability within Switzerland. The debate centers around the potential revision of the health insurance regulations, which would allow for price reductions on certain drugs. This proposal was introduced as part of broader efforts to control healthcare costs. However, industry representatives argue that these changes could have unintended consequences. They claim that the current system already allows for some level of cost containment while maintaining access to essential medicines. René Buholzer, head of Interpharma, the association representing Switzerland’s research-based pharmaceutical companies, expressed concern over the impact of U.S. pricing pressures on the Swiss market. He emphasized that the pharmaceutical sector plays a crucial role in the country's economy, contributing significantly to tax revenues. According to Buholzer, declining profitability in the industry could lead to reduced investment in research and development, ultimately limiting the availability of new treatments. Buholzer explained that the U.S. has implemented a reference pricing system, which uses prices from multiple countries, including Switzerland, to determine drug costs domestically. As a result, lower prices in Switzerland could negatively affect revenue in the larger American market. He noted that this dynamic has intensified in recent years, with the situation worsening due to stricter cost-control measures in Europe and increased scrutiny of pricing strategies globally. Interpharma’s analysis suggests that a third of medications approved by Swissmedic, the country’s drug regulatory authority, are no longer being reimbursed by health insurers. This trend highlights a growing gap between innovation and accessibility. The organization warns that continued pressure to reduce drug prices could further limit the availability of new therapies, particularly in areas requiring advanced medical treatment. The Swiss government has acknowledged the challenges facing the pharmaceutical sector but maintains that controlling healthcare costs remains a priority. Officials argue that introducing price discounts could help make medications more affordable for patients without compromising quality or safety. However, industry leaders counter that such measures fail to account for the complex interplay between international markets and domestic policy. Buholzer stressed that the pharmaceutical industry is open to discussing financial sustainability but cautioned against implementing policies that could undermine long-term viability. He pointed out that the current pricing structure is necessary to ensure competitiveness in global markets, especially given the influence of U.S. pricing decisions on Swiss firms. Without adequate support, he warned, the Swiss pharmaceutical sector could shrink significantly by 2040, leading to substantial economic losses. As the discussion continues, stakeholders remain divided on the best path forward. While policymakers seek to balance affordability with innovation, industry representatives emphasize the need for stable, predictable conditions to sustain growth and development. The outcome of this debate will likely shape the future of healthcare in Switzerland for years to come.